To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2 - Trial NCT05200741
Access comprehensive clinical trial information for NCT05200741 through Pure Global AI's free database. This Phase 2 trial is sponsored by The University of Hong Kong and is currently Recruiting. The study focuses on Covid19. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
The University of Hong Kong
Timeline & Enrollment
Phase 2
Feb 08, 2022
Feb 01, 2024
Primary Outcome
Reactogenicity,Adverse Events,Neutralizing Antibodies in Serum against Live SARS-CoV-2 Measured by Neutralization Assay,Binding Antibodies in Serum against SARS-CoV-2 RBD Measured by CMIA
Summary
To evaluate the safety and immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 as booster vaccine for
 COVID-19 in healthy adults who have received 2 doses of BNT162b2
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05200741
Non-Device Trial